It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 120 (1) , 1-4
Abstract
No abstract availableFunding Information
- BMS
- MSD
- Ono Pharmaceutical Company
- Roche
- MSD
This publication has 5 references indexed in Scilit:
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b studyThe Lancet Oncology, 2020
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 2020
- A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.Journal of Clinical Oncology, 2020
- CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)Annals of Oncology, 2019
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challengesNature Reviews Clinical Oncology, 2018